KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC - Summary - MDSpire
Clinical Guidelines
Feature

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

A perioperative regimen of enfortumab vedotin-ejfv plus pembrolizumab significantly improved survival and pathologic complete response rates compared to radical cystectomy alone in patients with muscl...

  • By

  • Chase Doyle

  • May 8, 2026

  • 6 min

Share

In a pivotal phase III trial (KEYNOTE-905), combining enfortumab vedotin-ejfv, an antibody-drug conjugate, with the PD-1 inhibitor pembrolizumab significantly enhanced event-free and overall survival rates in muscle-invasive bladder cancer (MIBC) patients who were ineligible for cisplatin chemotherapy. Presented at the 26th Annual Society of Urologic Oncology Meeting, this regimen yielded a pathologic complete response rate of 57.1% compared to 8.6% with radical cystectomy alone. This treatment represents a new standard of care, approved by the FDA, for patients with a high unmet medical need.

Original Source(s)

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

  • by Chase Doyle

  • May 8, 2026

Related Content

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book

ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book.    

  • by ASCO

  • May 8, 2026

  • 2 min
National Academy of Medicine Recognizes 100 Newly Elected Members

Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.